Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies

The design of a human immunodeficiency virus–1 (HIV-1) immunogen that can induce broadly reactive neutralizing antibodies is a major goal of HIV-1 vaccine development. Although rare human monoclonal antibodies (mAbs) exist that broadly neutralize HIV-1, HIV-1 envelope immunogens do not induce these antibody specificities. Here we demonstrate that the two most broadly reactive HIV-1 envelope gp41 human mAbs, 2F5 and 4E10, are polyspecific autoantibodies reactive with the phospholipid cardiolipin. Thus, current HIV-1 vaccines may not induce these types of antibodies because of autoantigen mimicry of the conserved membrane-proximal epitopes of the virus. These results may have important implications for generating effective neutralizing antibody responses by using HIV-1 vaccines.

[1]  E. Daar,et al.  Neutralization of HIV type 1 infectivity by serum antibodies from a subset of autoimmune patients with mixed connective tissue disease. , 1996, AIDS research and human retroviruses.

[2]  R. Asherson,et al.  Anticardiolipin, anti-β2-glycoprotein I and antiprothrombin antibodies in black South African patients with infectious disease , 2003, Annals of the rheumatic diseases.

[3]  C. Feighery,et al.  Antibodies to prothrombin in antiphospholipid syndrome and inflammatory disorders , 1998, British journal of haematology.

[4]  D. Isenberg,et al.  The prevalence of antibodies to anionic phospholipids in patients with the primary antiphospholipid syndrome, systemic lupus erythematosus and their relatives and spouses. , 2000, Rheumatology.

[5]  Wayne C Koff,et al.  HIV vaccine design and the neutralizing antibody problem , 2004, Nature Immunology.

[6]  M. Nussenzweig,et al.  Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development. , 2001, The Journal of clinical investigation.

[7]  M. Kazatchkine,et al.  Anti-cardiolipin antibodies are associated with anti-endothelial cell antibodies but not with anti-beta 2 glycoprotein I antibodies in HIV infection. , 1995, Clinical immunology and immunopathology.

[8]  H. Moutsopoulos,et al.  Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI. , 1999, Journal of autoimmunity.

[9]  D. Isenberg,et al.  Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. , 2002, Arthritis and rheumatism.

[10]  G. Ciliberto,et al.  Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay. , 2004, Journal of immunological methods.

[11]  E A Emini,et al.  Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. , 1997, AIDS research and human retroviruses.

[12]  Gennaro Ciliberto,et al.  Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. , 2003, Journal of molecular biology.

[13]  Ping Zhu,et al.  Antibody Domain Exchange Is an Immunological Solution to Carbohydrate Cluster Recognition , 2003, Science.

[14]  H. Katinger,et al.  The carbohydrate epitope of the neutralizing anti-HIV-1 antibody 2G12. , 2003, Advances in experimental medicine and biology.

[15]  J. Kearney,et al.  Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. , 2001, Immunity.

[16]  Pojen P. Chen,et al.  Characterization of IgG monoclonal anti‐cardiolipin/anti‐β2GP1 antibodies from two patients with antiphospholipid syndrome reveals three species of antibodies , 1999, British journal of haematology.

[17]  R. Palacios,et al.  Human immunodeficiency virus infection and systemic lupus erythematosus , 2004, International journal of STD & AIDS.

[18]  G. Dighiero,et al.  From Natural Polyreactive Autoantibodies to À La Carte Monoreactive Antibodies to Infectious Agents: Is It a Small World after All? , 1998, Infection and Immunity.

[19]  G. McGaughey,et al.  HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb. , 2003, Biochemistry.

[20]  H. Katinger,et al.  Anti-idiotypic antibody Ab2/3H6 mimics the epitope of the neutralizing anti-HIV-1 monoclonal antibody 2F5. , 2002, AIDS.

[21]  Allan Wiik,et al.  Detection of antinuclear antibodies by solid-phase immunoassays and immunofluorescence analysis. , 2004, Clinical chemistry.

[22]  Renate Kunert,et al.  Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. , 2005, Immunity.

[23]  H. Katinger,et al.  Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection. , 2003, The Journal of antimicrobial chemotherapy.

[24]  T. Barbui,et al.  Lupus Anticoagulant IgG's (LA) Are Not Directed to Phospholipids only, but to a Complex of Lipid-Bound Human Prothrombin , 1991, Thrombosis and Haemostasis.

[25]  W. Rozenbaum,et al.  Autoantibodies to Phospholipids and to the Coagulation Proteins in AIDS , 1997, Thrombosis and Haemostasis.